FDA OTC drug oversight funded by fees manufacturers will pass to consumers

What it does

This bill extends and revises the FDA's user-fee program for over-the-counter (OTC) monograph drugs—non-prescription medications like antacids and cough drops that are sold without individual drug applications. The bill authorizes the FDA to collect facility fees from OTC drug manufacturers from fiscal years 2026–2030, with specific revenue targets and adjustment mechanisms. The fees fund FDA review and oversight of OTC monograph drugs, and the bill includes technical updates to the fee structure, inflation adjustments, and a one-time workload adjustment option for fiscal years 2028–2030.

Why we flagged it

The bill's core function is straightforward—reauthorizing FDA user fees for OTC drug oversight through 2030. However, the inclusion of 'voluntary consensus standards' language and specific dollar-amount carve-outs (e.g., $2.373M for FY2026) suggests accommodation of industry preferences within the fee structure, blending public oversight with private-sector input.

What the text implies

• The 'voluntary consensus standard' definition in Section 3 may allow OTC drug manufacturers to influence testing procedures through industry-led standards bodies, potentially weakening FDA oversight if those standards are less stringent than FDA-mandated testing.
• The one-time facility fee workload adjustment (Section 4, paragraph 4) is triggered only if average OTC facilities exceed 1,625 AND fewer than 30% are on arrears lists—a narrow condition that may never activate, leaving the adjustment as a contingent benefit to manufacturers if market conditions align.
• Fee revenue amounts include specific dollar add-ons ($2.373M FY2026, $1.233M FY2027, $854K FY2028) that appear to be negotiated carve-outs rather than formula-driven, suggesting prior industry negotiation embedded in the bill.
• The bill sunsets October 1, 2030, requiring reauthorization; manufacturers may lobby for higher fee caps or weaker standards during the next reauthorization cycle, using this bill as a baseline.
• Consumers will likely bear fee costs through higher OTC drug prices, but the bill does not require price transparency or cap increases, leaving the pass-through mechanism unmonitored.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from continued FDA oversight of OTC drugs, which protects product safety and quality. However, manufacturers will pass fee costs to consumers through higher OTC drug prices, and the bill's voluntary consensus-standard language may weaken testing rigor if industry-friendly standards are adopted. The net effect on ordinary people depends on whether fee-funded oversight improvements outweigh price increases.

Who stands to gain

• OTC drug manufacturers and facility operators (fee-funded FDA oversight reduces their compliance unc
• Standards development organizations (increased industry reliance on voluntary consensus standards)
• FDA (fee revenue dedicated to OTC monograph activities)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), OTC drug manufacturers, Standards development organizations (national and international), House Committee on Energy and Commerce, Senate Committee on Health, Education, Labor, and Pensions

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Jul 2, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 2, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• Jul 23, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Jul 23, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported (Amended) by the Yeas and Nays: 51 - 0”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 9 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $2,175,234 in lobbying spend. A filing names 13 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Robert Latta, the sponsor, reported $876,626 in PAC receipts in the 2026 cycle.

• American Academy of Dermatology Association — $1,030,000 on 2 filings
• Consumer Healthcare Products Association — $445,234 on 2 filings
• National Treasury Employees Union — $350,000 on 1 filing
• Haleon Us Holdings LLC — $210,000 on 1 filing
• Chattem, Inc. Dba Opella — $60,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.